(20MMOL/L) POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION USP SOLUTION

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

SODIUM CHLORIDE; POTASSIUM CHLORIDE

Disponibbli minn:

BAXTER CORPORATION

Kodiċi ATC:

B05BB01

INN (Isem Internazzjonali):

ELECTROLYTES

Dożaġġ:

900MG; 150MG

Għamla farmaċewtika:

SOLUTION

Kompożizzjoni:

SODIUM CHLORIDE 900MG; POTASSIUM CHLORIDE 150MG

Rotta amministrattiva:

INTRAVENOUS

Unitajiet fil-pakkett:

1000ML

Tip ta 'preskrizzjoni:

Ethical

Żona terapewtika:

REPLACEMENT PREPARATIONS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0213340001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2012-12-07

Karatteristiċi tal-prodott

Potassium Chloride in 0.9% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 1 of 15_
PRESCRIBING INFORMATION
POTASSIUM CHLORIDE IN 0.9% SODIUM CHLORIDE INJECTION, USP
IN PLASTIC CONTAINER
VIAFLEX
Container
20mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection
40mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection
SOLUTION FOR INFUSION
Solutions Affecting the Electrolyte Balance
BAXTER CORPORATION
Mississauga, ON L5N 0C2
Date of Revision:
December 10, 2018
Control No. 221539
Potassium Chloride in 0.9% Sodium Chloride Injection, USP Prescribing
Information
_ _
_Page 2 of 15_
TABLE OF CONTENTS
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
INSTRUCTIONS FOR USE AND HANDLING AND DISPOSAL
................................11
DIRECTIONS FOR USE OF VIAFLEX PLUS PLASTIC CONTAINER
......................11
OVERDOSE
......................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................13
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
Potassium Chloride in 0.9% Sodium Chlo